Sotrovimab-linked SARS-CoV-2 mutations emerge in Sydney
Cases of resistance to the biologic demand increased genomic surveillance, virologists say
Signs of SARS-CoV-2 resistance to sotrovimab, the main monoclonal antibody treatment used in Australia, has been detected in a world-first clinical study in Sydney.
The discovery will likely lead to intense genomic monitoring of patients to ensure resistance doesn’t render the drug ineffective, researchers say.